Overview

Biocartis is a molecular diagnostics company headquartered in Mechelen, Belgium, founded in 2007. It makes the Idylla Platform, a fully automated real-time PCR system, and offers mutation assays for several cancers as well as infectious disease tests. The company serves pharmaceutical companies, healthcare providers, and research institutions, employs roughly 200 to 500 people, and is privately held. In June 2026 it announced an agreement with City of Hope to explore a rapid gene signature test for early detection of pancreatic cancer.

At a glance

What Biocartis makes

The company holds ISO 13485 certification and provides automated molecular diagnostic testing through its Idylla Platform, which uses real-time PCR technology.

Certifications

Biocartis is associated with the following certifications in public sources. Confirm the certified scope for the specific plant producing your part:

• ISO 13485 — biocartis.com

Latest developments

• 2026-10-30 — Press Release Biocartis NV: Biocartis to Present Initial (globenewswire.com)

• 2026-10-30 — Press Releases | Biocartis (biocartis.com)

• 2026-07-07 — Discovery Life Sciences and Biocartis Announce Strategic Collaboration to Advance Precision Oncology Diagnostics | Discovery Life Sciences (dls.com)

• 2026-06-09 — Biocartis, City of Hope Explore Development of Rapid Pancreatic Cancer Test | GenomeWeb (genomeweb.com)

• 2026-06-09 — Press Release Biocartis NV: Biocartis Announces Agreement with City of Hope to Explore Development of Rapid Gene Signature Test for Early Detection of Pancreatic Cancer - BioSpace (biospace.com)

• 2026-04-22 — Biocartis US Added to DLA $10M Lab Equipment and Consumables IDIQ Contract | Contract Awards (envzone.com)

Facilities

Biocartis is headquartered in Mechelen, Flanders. Public sources also reference these locations:

• Mechelen, Belgium — biocartis.com

Company details

Biocartis is a privately held company with an estimated annual revenue of $50 to $100 million and a workforce of 200 to 500 employees. Biocartis was founded in 2007, has an estimated 200-500 employees, and is headquartered in Mechelen, Flanders. On the LightSource stability read it is rated "Established & active": 19 years in operation (founded 2007). Holds ISO 13485 certification(s) per public sources.

Frequently asked questions

What does Biocartis make?

Biocartis is a molecular diagnostics company headquartered in Mechelen, Belgium, founded in 2007. It makes the Idylla Platform, a fully automated real-time PCR system, and offers mutation assays for several cancers as well as infectious disease tests. The company serves pharmaceutical companies, healthcare providers, and research institutions, employs roughly 200 to 500 people, and is privately held. In June 2026 it announced an agreement with City of Hope to explore a rapid gene signature test for early detection of pancreatic cancer.

Where is Biocartis headquartered?

Biocartis is headquartered in Mechelen, Flanders.

When was Biocartis founded?

Biocartis was founded in 2007.

How big is Biocartis?

Biocartis has an estimated 200-500 employees, with revenue in the $50-100M range (estimated).

What certifications does Biocartis hold?

Biocartis lists ISO 13485 on its website. Confirm the certified scope for the specific plant producing your part.

Related suppliers

Explore other suppliers in the LightSource directory:

• 10xEngineers

• 1X

• 365 Retail Markets

• 3Com

• 3PAR

Last verified Nov 2026. Is this your company? Request a correction.